Companies Dominating the Myositis Treatment Landscape
- Baxter International, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- Novartis AG
- Sanofi-aventis Groupe
- Abbott Laboratories
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Siemens Healthcare GmbH
- Pfizer Inc.
- Becton, Dickinson and Company
- IBSRELA
- Indegene
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of myositis treatment is assessed at USD 725.4 million.
The myositis treatment market size was valued at USD 677.95 million in 2024 and is expected to reach USD 1.17 billion by 2037, expanding at around 4.3% CAGR during the forecast period i.e., between 2025-2037. Growing geriatric population and increasing cases of myositis amongst the older population will boost the market growth
North America industry is expected to dominate majority revenue share of 37% by 2037, led by increasing frequency of musculoskeletal disorders amongst several people.
The major players in the market are Baxter International, Inc., Eli Lilly and Company, Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., Becton, Dickinson and Company, IBSRELA, Indegene
